
|Articles|June 24, 2004
Organizations work to streamline approval of prostate cancer drugs
Four leading prostate cancer advocacy groups are working in cooperation with the FDA to streamline the approval process of critical prostate cancer treatments by changing clinical trial endpoints, without compromising safety.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
5






